Study of Early Lymphopheresis for Relapsed/Refractory DLBCL Sheds Light on CAR-T Efficacy
Researchers explored early lymphopheresis for CD19-based chimeric antigen receptor T-cell therapy for relapsed/refractory DLBCL.
Diagnosis & Disease Information
CAR T-Cells May Be Safe in Non-Transplant Eligible Patients With Large B-Cell Lymphoma
Researchers sought to determine whether CAR-T therapy would be a viable option for patients with relapsed/refractory large B-cell lymphoma.
Intervention Training Oncology Nurses Improves Management of CAR-T Therapy
A team of HSCT nurses developed a training program for oncology nurses to improve the care of patients with hematologic cancer outside the transplantation unit.
Survey Reveals Physician Preferences for Treating Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Researchers sought to determine physician preferences for treating patients with relapsed/refractory diffuse large B-cell lymphoma in the third line setting.
CAR T Cells Targeting GD2 Feasible, Safe for Pediatric Neuroblastoma
GD2-targeted CAR T cells expanded in vivo, and were detectable in peripheral blood up to 30 months after infusion.
Anti-GPRC5D CAR-T Therapy Elicits Responses After Anti-BCMA CAR Failure
Anti-GPRC5D CAR T-cell therapy can produce responses in patients with relapsed or refractory multiple myeloma, a phase 2 trial suggests.
CAR-T Survival Outcomes Unrelated to Household Poverty and Neighborhood Opportunity in ALL
Researchers sought to determine whether OS rates with CAR-T therapy were linked to household poverty and neighborhood opportunity for patients with ALL.
Responses Fleeting With CAR-T Reinfusion in Children, AYAs With B-ALL
Reinfusion with the CAR T-cell therapy tisagenlecleucel does not produce durable remissions in children and AYAs with B-ALL, a study suggests.
Tecartus Approved for Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
The approval was based on data from the phase 1/2 ZUMA-3 trial which evaluated Tecartus in 71 adults with relapsed or refractory B-cell precursor ALL.
Unmet Need Seen in Patients With B-Cell Lymphoma Who Fail CAR-T Therapy
Researchers sought to determine the unmet need in patients with aggressive B-cell lymphomas whose disease relapses after CAR-T therapy.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...